ReviewMicromachines2022
2D MXene Nanomaterials as Electrocatalysts for Hydrogen Evolution Reaction (HER): A Review.
Review in Micromachines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Synthesis and Surface Engineering of Two-Dimensional MXenes for Advanced Functional Applications.Chemical record (New York, N.Y.) · 2026Review
- Aqueous MXene-Assisted Charge Transport for Sliding Cu/n-Si DC Triboelectric Nanogenerators.Nanomaterials (Basel, Switzerland) · 2026Article
- Review
- La-Ni-MOF(BDC) composite with graphene oxide for enhanced bifunctional electrocatalysis in electrochemical water splitting.Scientific reports · 2026Article
- Engineering MXene/metal composites from MAX phase/metal-Al precursors for high-performance energy conversion and storage.RSC advances · 2025Article
- γ-Graphyne as a Functional 2D Nanoarchitectonics for Room-Temperature Chemiresistive-Potentiometric Sensing Interfaces.ACS sensors · 2025Article
- Article
- Materials Nanoarchitectonics at Dynamic Interfaces: Structure Formation and Functional Manipulation.Materials (Basel, Switzerland) · 2024Review
- Progress in the Synthesis Process and Electrocatalytic Application of MXene Materials.Materials (Basel, Switzerland) · 2023Review
- Research progress on black phosphorus hybrids hydrogel platforms for biomedical applications.Journal of biological engineering · 2023Review
- Molecular Machines and Microrobots: Nanoarchitectonics Developments and On-Water Performances.Micromachines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
MXenes, a novel family of 2D transition metal carbide, nitride and carbonitride materials, have been gaining tremendous interest in recent days as potential electrocatalysts for various electrochemical reactions, including hydrogen evolution reaction (HER). MXenes are characterized by their etchable metal layers, excellent structural stability, versatility for heteroatoms doping, excellent electronic conductivity, unique surface functional groups and admirable surface area, suitable for the role of electrocatalyst/support in electrochemical reactions, such as HER. In this review article, we summarized recent developments in MXene-based electrocatalysts synthesis and HER performance in terms of the theoretical and experimental point of view. We systematically evaluated the superiority of the MXene-based catalysts over traditional Pt/C catalysts in terms of HER kinetics, Tafel slope, overpotential and stability, both in acidic and alkaline electrolytic environments. We also pointed out the motives behind the electro catalytic enhancements, the effect of synthesis conditions, heteroatom doping, the effect of surface terminations on the electrocatalytic active sites of various MXenes families. At the end, various possible approaches were recommended for a deeper understanding of the active sites and catalytic improvement of MXenes catalysts for HER.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.